NGM Biopharmaceuticals
NGM Biopharmaceuticals advances a diverse pipeline of biologic drug candidates discovered in-house, focusing on unmet medical needs in cancer and other diseases. Headquartered in South San Francisco, the company is committed to accessibility, diversity, and inclusion, and partners with Level Access to ensure digital accessibility.
Company Overview
NGM Biopharmaceuticals is headquartered at 333 Oyster Point Blvd, South San Francisco, CA 94080. The company advances a broad and diverse pipeline of biologic drug candidates, all discovered in-house. With a focus on addressing significant unmet medical needs in cancer and other diseases, NGM Biopharmaceuticals is setting new standards for the future of cancer care.
Biologic Drug Pipeline
NGM Biopharmaceuticals has a unique set-up covering everything from research to late-stage development. The company recently announced new clinical data from an ongoing trial of NGM707 in advanced solid tumors. Additionally, NGM outlines an evolved strategy for Aldafermin and NGM120 to focus on rare conditions with significant unmet need. The company's commitment to exploring partnering opportunities enhances its ability to address critical health challenges.
Commitment to Accessibility and Inclusion
NGM Biopharmaceuticals is committed to accessibility, diversity, and inclusion. The company aims to comply with W3C’s WCAG 2.1 Level A and AA guidelines and has partnered with Level Access to ensure its digital properties are accessible to all individuals. This commitment underscores NGM’s dedication to creating an inclusive environment for both its digital users and over 150 employees.
Headquarters
NGM Biopharmaceuticals is headquartered in South San Francisco, CA. The headquarters, located at 333 Oyster Point Blvd, anchors the company's operations, which range from research and development to late-stage clinical trials. The location also serves as the hub for NGM’s initiatives to set new standards in cancer care and address significant unmet medical needs.